| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 2,019 | 2,019 |
| Net increase (decrease) in cash and cash equivalents | -20,403 | -22,835 |
| Cash and cash equivalents at beginning of period | 27,727 | - |
| Cash and cash equivalents at end of period | 7,324 | - |
NextCure, Inc. (NXTC)
NextCure, Inc. (NXTC)